Is Real-world Data Latency Holding Back Your Commercial Strategy?
How Japanese pharma leaders are embracing Patient-centric Intelligence
Japanese pharmaceutical leaders are moving beyond data latency concerns to focus on a more crucial question: How can patient data drive commercial success? The answer lies in understanding its strategic value.
Understanding Regional Performance Variations in Japanese Pharmaceutical Markets
Unlock the complex drivers behind regional performance variations in Japan’s pharmaceutical market through facility-level analysis that reveals actionable insights beyond traditional sales data approaches.
First-Mover Advantage in Japan
Facility-Level Intelligence is a Strategic Imperative
In Japan’s hospital-centric healthcare system, early adoption of facility-level intelligence creates lasting competitive advantages. Learn how sophisticated analytics drive better performance, protocol adoption, and patient care across specialist institutions.
Cracking the Code of Multi-Indication Drugs
Moving Beyond Traditional Data Sources
Multi-indication drugs open new possibilities for pharmaceutical marketing but also bring unique challenges. Approved for multiple conditions, these treatments require a targeted, data-driven strategy to unlock their full potential across diverse therapeutic areas. In Japan, traditional sales and distribution data fall short in revealing specific usage patterns, risking missed opportunities and inefficient resource allocation. A more nuanced approach is essential to capture untapped potential and enhance patient access.
Australian Health Innovators’ Journey to US Market Success
Reflections from AusBiotech 2024
Drawing from recent conversations with Australian healthcare innovators, including discussions at AusBiotech 2024, Dr. Peter Cronin explores the evolving challenges of US market entry. He shares insights on how companies are moving beyond traditional approaches to embrace data-driven, patient-centric strategies for global success.
Taking Brand Intelligence From National to Hyperlocal
Maximizing Opportunities and Mitigating Risks with Prospection AI and Facility Insights
The ability to see and act on facility-level insights is not just an advantage – it’s a necessity. With Prospection AI and Facility Insights, pharmaceutical companies are equipped to treat patients with greater precision and confidence, driving both business success and improved patient outcomes.
Unlocking US Market Potential
How Patient-centric Intelligence Guides Emerging Biotech and Medical Device Companies
Patient-centric intelligence (PCI) offers Australian biotech and medical device companies a powerful tool for navigating the US healthcare market. Discover how PCI can unlock market potential, mitigate risks, and strengthen pitches to partners and investors.
Breaking Down Silos
How Patient-Centric Intelligence (PCI) Platforms Can Boost Collaborative Brand Management
Learn how Patient-Centric Intelligence (PCI) platforms can enhance collaborative brand management in the pharmaceutical industry. By integrating data and fostering cross-functional teamwork, PCI platforms empower teams to make informed decisions that improve patient outcomes and optimise brand performance. Discover how breaking down silos can lead to more effective, patient-centric strategies.
Prospection CEO Daniel West on Patient-Centric Intelligence and Category Creation
Prospection’s CEO Daniel West discusses the journey to build the future of patient-centric intelligence, unpacking the role that category design plays in defining business strategy and strengthening the company’s goal to address care and share leaks in pharma. Listen to the podcast to learn more.
Unleashing India’s Analytical Prowess to Advance Patient-centric Intelligence
Now Hiring for Analytics Center of Excellence
Prospection is opening an Analytics Center of Excellence (ACE) in India, tapping into the country’s reputation as a global analytics powerhouse. This strategic move will strengthen our ability to deliver patient-centric intelligence to life sciences companies across the U.S., Japan, and Australia, powered by our flagship product, Prospection AI. We’re actively recruiting talented individuals to join our team in India and help transform healthcare through the power of data analytics and AI.
Navigating the Complexity of Patient Data: Why Pharma Needs Specialized Intelligence Platforms
Generic analytics tools often fail to address the complexity of patient data in pharma. Learn why putting specialized intelligence platforms in the hands of analytics as well as commercial teams is essential for generating actionable insights that drive better patient outcomes and commercial success.
Reflections from Tokyo: Prospection’s Pharma Executive Roundtable on AI and Generative AI
Bruce Goodwin, former President of Janssen Japan and Managing Director of Janssen ANZ as well as Prospection Board member, shares his reflections and key takeaways from moderating Prospection’s Pharma Executive Roundtable on AI and Generative AI in Tokyo. Get Bruce’s take on how these technologies are transforming drug commercialization and the challenges and opportunities they present.
